Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders
Description
Disorders characterized by proliferation of lymphoid tissue, general or unspecified. MeSH
Hierarchy View
Subtype Terms (21)
Agammaglobulinemia
24 drugs (22 approved, 2 experimental)
Autoimmune Lymphoproliferative Syndrome
5 approved drugs
Castleman Disease
22 drugs (20 approved, 2 experimental)
Granuloma
38 drugs (29 approved, 9 experimental)
Immunoblastic Lymphadenopathy
1 approved drug
Immunoglobulin Light-chain Amyloidosis
54 drugs (40 approved, 14 experimental)
Immunoproliferative Small Intestinal Disease
Infectious Mononucleosis
7 drugs (4 approved, 3 experimental)
Leukemia, Hairy Cell
88 drugs (61 approved, 27 experimental)
Leukemia, Lymphoid
134 drugs (80 approved, 54 experimental)
Lymphangiomyoma
1 approved drug
Lymphoma
962 drugs (373 approved, 589 experimental)
Macrophage Activation Syndrome
8 drugs (7 approved, 1 experimental)
Multiple Myeloma
862 drugs (291 approved, 571 experimental)
Plasmacytoma
86 drugs (59 approved, 27 experimental)
Sarcoidosis
53 drugs (41 approved, 12 experimental)
Sezary Syndrome
122 drugs (80 approved, 42 experimental)
Tumor Lysis Syndrome
4 approved drugs
Waldenstrom Macroglobulinemia
171 drugs (92 approved, 79 experimental)
Phase 4 Indicated Drugs (5)
Phase 2 Indicated Drugs (47)
allogeneic hematopoietic stem cells (Hemacord)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous immunoglobulin idiotype-klh conjugate vaccine
Phase 1 Indicated Drugs (26)
autologous ebv-ctl transduced with vector sfg-cna12
autologous ebv specific cytotoxic t lymphocytes
autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine
ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine
Other Experimental Indicated Drugs (9)
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (17)
Organization Involved with Phase 2 Indications (48)
Korea Research Institute of Bioscience & Biotechnology
Methodist Cancer Center, Houston, Texas
State University of New York, Buffalo
The University of Texas, Dallas
University of California, San Diego
Organization Involved with Phase 1 Indications (21)
Organization Involved with Other Experimental Indications (4)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.